MedTrace Logo

Pharmacogenetic Testing in an Outpatient Population of Patients With Depression

NCT02497027 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 83

Last updated 2017-05-03

No results posted yet for this study

Summary

This is a randomized, control group design of pharmacogenetic implementation in a mental health population of subjects taking anti-depressants and/or anti-psychotics with a new or current primary or secondary diagnosis of Major Depressive Disorder (MDD) or Depressive Disorder Not Otherwise Specified (DDNOS).

Conditions

Interventions

OTHER

pharmacogenetic testing

pharmacogenetic testing report released to physician at 4 weeks post enrollment

OTHER

pharmacogenetic testing

pharmacogenetic testing report released to physician at 12 weeks post enrollment

Sponsors & Collaborators

  • Avera McKennan Hospital & University Health Center

    lead OTHER

Principal Investigators

  • Matthew Stanley, MD · Avera McKennan Hospital & University Health Center

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2017-04-01
Completion
2017-04-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02497027 on ClinicalTrials.gov